Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$66.82 USD

66.82
781,038

+1.25 (1.91%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $66.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 21 - 40 ( 304 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 21

12/15/2022

Company Report

Pages: 10

Cytokinetics Now; Omecamtiv Appears To Have Been Clearing Event for Investors; Target Upped to $56

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 22

12/14/2022

Company Report

Pages: 10

Omecamtiv Takes It On the Chin; Playing It Safe and Removing From Valuation; Target Reduced to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 23

12/09/2022

Daily Note

Pages: 6

Briefing Docs Contain No Real Surprises; Looking Forward to Vibrant Discussion on Tuesday

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 24

12/08/2022

Company Report

Pages: 7

KOL Provides Upbeat Perspective Ahead of Omecamtiv AdCom Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 25

12/07/2022

Daily Note

Pages: 9

Clinical Pipeline Expands With an Additional Phase 1 Study of CK-136 in HF

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 26

12/06/2022

Daily Note

Pages: 4

Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 27

12/04/2022

Daily Note

Pages: 4

Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 28

11/09/2022

Company Report

Pages: 11

Omecamtiv Filing Accepted in China as Excitment Brews Here for AdCom; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 29

11/07/2022

Company Report

Pages: 10

New Data Demonstrate Omecamtiv''s Economic and Clinical Benefit For Men and Women Alike

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 30

11/04/2022

Company Report

Pages: 10

3Q22 Results; Quite Busy Ahead of Critical AdCom; We Look Toward Positive Outcome

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 31

10/03/2022

Company Report

Pages: 9

Parallel REDWOOD-HCM OLE Updates Echo Aficamten''s Promise in HCM

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 32

08/05/2022

Company Report

Pages: 7

2Q22 Results; AdCom and PDUFA Dates on the Horizon; Things Getting Real Exciting

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 33

06/17/2022

Company Report

Pages: 6

Omecamtiv''s PDUFA Extended on PK Data Fine-Tuning; Our Thesis Remains Unaltered

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 34

06/13/2022

Daily Note

Pages: 6

Echo Measures Showcase Early Benefits of Aficamten on Cardiac Structure and Function at ASE

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 35

05/24/2022

Company Report

Pages: 10

Longer-Term Aficamten Data at ESC-HF Do Not Disappoint; Omecamtiv Continues to Strengthen Its Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 36

05/05/2022

Company Report

Pages: 7

1Q22 Results; Late Stage Execution Continues According to Plan

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 37

04/29/2022

Company Report

Pages: 7

Mavacamten Crosses the Finish Line; We are Confident Aficamten Is Next and Could Do Better; Target Increased to $75

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 38

04/04/2022

Company Report

Pages: 10

Cardiac Myosin Inhibitors Shine at ACC.22; Full REDWOOD-HCM Cohort 3 Results Impress

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 39

02/25/2022

Company Report

Pages: 7

2021 Results; Late Stage Execution Continues With Solid Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 40

02/15/2022

Daily Note

Pages: 5

METEORIC-HF Fails; Omecamtiv''s Journey to Regulatory Approval Remains Unaltered, We Believe

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party